This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Select Medical (SEM) Q2 Earnings Beat, Raises '21 EPS View
by Zacks Equity Research
Select Medical's (SEM) second-quarter results reflect strong top-line growth, higher admissions and increased patient visits, partly offset by elevated costs.
Acadia Healthcare's (ACHC) Solid Results Lead to Stock Rally
by Zacks Equity Research
Acadia Healthcare Company (ACHC) gains from rising demand for its behavioral healthcare services and investors' optimism on clarity about its growth strategies.
Ensign Group (ENSG) Buyouts to Bolster Its Position in Texas
by Zacks Equity Research
Ensign Group (ENSG) buys operations in Texas to boost its portfolio and also strengthen its relationship with CareTrust REIT.
Acadia Healthcare (ACHC) Beats on Q2 Earnings, Ups '21 EPS View
by Zacks Equity Research
Acadia Healthcare's (ACHC) second-quarter results highlight rise in revenues, courtesy of increased volumes and facility expansions, partly offset by high costs.
Community Health (CYH) Q2 Earnings Beat, Hikes '21 EPS View
by Zacks Equity Research
Community Health's (CYH) second-quarter results indicate higher revenues and strong admission growth, partly offset by elevated expenses.
Encompass Health (EHC) Beats on Q2 Earnings, Hikes '21 View
by Zacks Equity Research
Encompass Health's (EHC) second-quarter results highlight growing revenues stemming from strong segmental performances, partly offset by elevated costs.
Universal Health Services (UHS) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Universal Health (UHS) Beats on Q2 Earnings, Ups '21 EPS View
by Zacks Equity Research
Universal Health's (UHS) second-quarter results reflect growing revenues attributable to strong segmental performances, partly offset by elevated expenses.
Universal Health Services (UHS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 36.73% and 5.74%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Universal Health's (UHS) Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) second-quarter results are likely to reflect improving revenues stemming from growing patient admissions, partly offset by high costs.
Earnings Preview: Universal Health Services (UHS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Universal Health Services (UHS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Universal Health (UHS), Beaumont Health to Offer Behavioral Care
by Zacks Equity Research
Universal Health's (UHS) joint venture (Beaumont Behavioral Health) with Beaumont Health will address the mental health issues in Southeast Michigan and across the state.
Zacks Industry Outlook Highlights: HCA Healthcare, Universal Health Services, Tenet Healthcare and Acadia Healthcare
by Zacks Equity Research
Zacks Industry Outlook Highlights: HCA Healthcare, Universal Health Services, Tenet Healthcare and Acadia Healthcare
4 Hospital Stocks to Gain From Rising Admissions, Aging Demography
by Zacks Equity Research
Expanding patient volumes, use of telehealth services, cost-control efforts and an aging demography are tailwinds to the hospital industry.
Here's Why You Should Hold on to Universal Health (UHS) Now
by Zacks Equity Research
Banking on its Acute Care and Behavioral Health platforms along with a robust capital position, Universal Health (UHS) holds potential to reap benefits for investors.
Tenet Healthcare (THC) to Divest Hospitals for $1.1 Billion
by Zacks Equity Research
Tenet Healthcare (THC) to sell five hospitals to Steward Health Care System, LC for a deal value of $1.1 billion.
Tenet Healthcare (THC) Soars 69% YTD: More Room to Run?
by Zacks Equity Research
Banking high on a solid guidance and strategic measures, Tenet Healthcare (THC) holds enough potential to reap benefits for investors.
Zacks Industry Outlook Highlights: Tenet Healthcare, Universal Health Services, Acadia Healthcare and Community Health Systems
by Zacks Equity Research
Zacks Industry Outlook Highlights: Tenet Healthcare, Universal Health Services, Acadia Healthcare and Community Health Systems
3 Stocks to Watch as Hospital Industry Stages a Recovery
by Zacks Equity Research
Strategic buyouts, divestitures, better volumes and cost-cutting measures are expected to aid hospital companies like ACHC, THC and CYH.
Why Is Universal Health Services (UHS) Up 9.5% Since Last Earnings Report?
by Zacks Equity Research
Universal Health Services (UHS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tenet Healthcare (THC) Offers Senior Notes Worth $1.4 B
by Zacks Equity Research
Tenet Healthcare (THC) exhibits prudence by issuing notes to procure funds and pay down its existing debt.
Acadia Healthcare (ACHC) Q1 Earnings Top Estimates, Rise Y/Y
by Zacks Equity Research
Acadia Healthcare (ACHC) Q1 earnings benefit from revenue gains, led by higher revenue per patient day and an increase in patient days, partly offset by a rise in expenses.
Community Health (CYH) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Community Health's (CYH) first-quarter results reflect decline in operating and interest expenses, partly offset by weaker admissions.
Encompass Health (EHC) Q1 Earnings Beat, Hikes '21 View
by Zacks Equity Research
Encompass Health's (EHC) first-quarter results reflect improved Inpatient Rehabilitation segment revenues, partly offset by lower volumes in both its segments and higher costs.
Universal Health (UHS) Q1 Earnings Top, Revenues Improve Y/Y
by Zacks Equity Research
Universal Health's (UHS) first-quarter results highlight uptick in revenues across both the company's segments, partly offset by escalating costs.